Clinical Trials

393 enrolled

Breast Neoplasms

NCT07307287 2025-12-29

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Breast Neoplasms

NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

120 enrolled

HR Positive HER2 Negative Advanced Breast Cancer

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

155 enrolled

Phase NA Not yet recruiting

HR+/HER2- Advanced Breast Cancer

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

40 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

52 enrolled

HR+/HER2- Advanced Breast Cancer

NCT06684600 2024-11-12

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

35 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Breast Neoplasms

NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Gynecologic

Ovarian Neoplasms

NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Phase 1 Recruiting

6 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06363734 2024-04-16

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

32 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06149130 2024-04-15

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

82 enrolled

Breast Neoplasms

NCT06341894 2024-04-02

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

1,163 enrolled

Breast Neoplasms

NCT06225921 2024-03-06

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Recruiting

6 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05949541 2024-02-08

BCTOP-L-M01

265 enrolled

Breast Neoplasms

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

200 enrolled

Breast Cancer Metastatic

NCT05759572 2024-02-06

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

145 enrolled

Breast Cancer Metastatic

NCT06243185 2024-02-06

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

Gynecologic

Ovarian Neoplasms

NCT06199271 2024-01-22

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06133088 2023-11-15

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

53 enrolled

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

236 enrolled

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

Phase 1/2 Unknown

59 enrolled

Breast Neoplasms

NCT05480280 2023-02-28

FIND

18 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05577442 2022-10-19

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

52 enrolled

Breast Neoplasm Female

NCT05586841 2022-10-19

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Phase 1 Unknown

HR+/HER2- Advanced Breast Cancer

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

12 enrolled

Breast Neoplasms

NCT05512416 2022-08-23

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

35 enrolled

Breast Neoplasms

NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Other solid neoplasm

Solid Tumor

NCT05431504 2022-06-24

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

53 enrolled